Label: HOMATROPINE HYDROBROMIDE OPHTHALMIC- homatropine hydrobromide solution

  • NDC Code(s): 59390-192-05
  • Packager: Altaire Pharmaceuticals Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated October 28, 2022

If you are a consumer or patient please visit this version.

View All Sections
  • SPL UNCLASSIFIED SECTION

    HOMATROPINE HYDROBROMIDE
    OPHTHALMIC SOLUTION, USP
    Rx only

    Established name:
    Homatropine Hydrobromide

    Chemical Name:
    Benzeneacetic acid, ɑ-hydroxy-, 8-methyl-8-azabicyclo [3.2.1]-oct-3-yl ester, hydrobromide, endo-(±)-. The active ingredient is represented by the chemical structure:

                      The chemical structure for Benzeneacetic acid.

    Each mL contains: Active: Homatropine Hydrobromide 5.0%. Preservative: Benzalkonium Chloride 0.005%. Inactive: Boric Acid, Edetate Disodium, Potassium Chloride, Water for Injection. Boric Acid or Sodium Carbonate may be added to adjust the pH.

  • INDICATIONS AND USAGE:

    A moderately long-acting mydriatic and cycloplegic for cycloplegic refraction and in the treatment of inflammatory conditions of the uveal tract. For pre and postoperative states when mydriasis is required. Use as an optical aid in some cases of axial lens opacities.

  • DOSAGE AND ADMINISTRATION:

    For refraction, instill one or two drops topically in the eye(s). May be repeated in five or ten minutes if necessary. For uveitis, instill one or two drops topically up to every three to four hours. Individuals with heavily pigmented irides may require larger doses.

  • CONTRAINDICATIONS:

    Contraindicated in persons with primary glaucoma or a tendency toward glaucoma, e.g. narrow anterior chamber angle, and in those persons showing hypersensitivity to any component of this preparation.

  • WARNING:

    For topical use only – not for injection. Risk-benefit should be considered when the following medical problems exist: keratoconus (Homatropine may produce fixed dilated pupil); Down’s syndrome, children with brain damage and the elderly (increased susceptibility). In infants and small children, use with extreme caution. Excessive use in pediatric patients or certain individuals with a history of susceptibility to belladonna alkaloids may produce systemic symptoms of homatropine poisoning (see overdose section).

  • PRECAUTIONS:

    General.

    To avoid excessive systemic absorption, the lacrimal sac should be compressed by digital pressure for two to three minutes after installation. To avoid inducing angle closure glaucoma, an estimation of the depth of the angle of the anterior chamber should be made. Excessive topical use of this drug can potentially lead to a confusional state characterized by delirium, agitation, and rarely coma. This state is more apt to occur in the pediatric and geriatric age groups. The specific anti-dote for this systemic anticholinergic syndrome is injectable physostigmine salicylate.

    Information to Patients.

    Patient should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patient may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child’s mouth and to wash their own hands and the child’s hands following administration. Do not touch dropper tip to any surface, as this may contaminate the solution.

  • ADVERSE REACTIONS:

    Transient symptoms of stinging and burning may occur. Prolonged use may produce local irritation characterized by follicular conjunctivitis, vascular congestion, edema, exudates, and an eczematoid dermatitis. Thirst or dryness of mouth, eye irritation not present before therapy, or increased sensitivity of eyes to light may occur.

    To report SUSPECTED ADVERSE REACTIONS, contact Altaire Pharmaceuticals, Inc. at (800)-258-2471.

    Pregnancy.

    Pregnancy Category C. Animal reproduction studies have not been conducted with homatropine hydrobromide. It is also not known whether homatropine hydrobromide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Homatropine Hydrobromide should be given to a pregnant woman only if clearly needed.

    Nursing Mothers.

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when homatropine hydrobromide is administered to a nursing woman

    Pediatric Use:

    Homatropine should not be used during the first three months of life due to a possible association between the cycloplegia produced and the development of amblyopia.

    Safety and effectiveness in pediatric patients have not been established.

  • OVERDOSAGE:

    When signs and symptoms of homatropine toxicity develop (see adverse reaction section), physostigmine should be administered parenterally (for dosage refer to Goodman & Gilman or other pharmacology reference). In infants and pediatric patients, the body surface must be kept moist.

  • DESCRIPTION:

    Homatropine hydrobromide is an anticholinergic prepared as a sterile topical ophthalmic solution.

  • CLINICAL PHARMACOLOGY:

    This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia).

    Carcinogenesis, Mutagenesis, Impairment of Fertility:

    There have been no long-term studies done using homatropine hydrobromide in animals to evaluate carcinogenic potential.

  • HOW SUPPLIED:

    5mL size in a white plastic bottle
    5mL - NDC 59390-192-05

    Storage:

    Store at 15° - 30°C (59°- 86°F).

    Caution: Federal (USA) law prohibits dispensing without prescription.

    Mfd. by: Altaire Pharmaceuticals, Inc
    Aquebogue, NY 11931

                                                                      R05/13
    F# 16545

  • PRINCIPAL DISPLAY PANEL

    PRINCIPAL DISPLAY PANEL

    NDC 59390-192-05
    Homatropaire
    Homatropine Hydrobromide
    Ophthalmic Solution, USP 5%
    5 mL- Sterile
    Rx Only

    NDC 59390-192-05 Homatropaire Homatropine Hydrobromide Ophthalmic Solution, USP 5% 5 mL- Sterile Rx Only

  • INGREDIENTS AND APPEARANCE
    HOMATROPINE HYDROBROMIDE OPHTHALMIC 
    homatropine hydrobromide solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:59390-192
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    HOMATROPINE HYDROBROMIDE (UNII: BEW7469QZ0) (HOMATROPINE - UNII:8QS6WCL55Z) HOMATROPINE HYDROBROMIDE50 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)  
    BORIC ACID (UNII: R57ZHV85D4)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    POTASSIUM CHLORIDE (UNII: 660YQ98I10)  
    WATER (UNII: 059QF0KO0R)  
    SODIUM CARBONATE (UNII: 45P3261C7T)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:59390-192-055 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product06/01/2018
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other06/01/2018
    Labeler - Altaire Pharmaceuticals Inc. (786790378)
View All Sections

Find additional resources

(also available in the left menu)

Safety

Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk

Related Resources

Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary

More Info on this Drug

View Labeling Archives, RxNorm, Get Label RSS Feed, View NDC Code(s)NEW!